Evan Seigerman analyst BMO

Currently out of the existing stock ratings of Evan Seigerman, 116 are a BUY (56.59%), 74 are a HOLD (36.1%), 15 are a SELL (7.32%).

Evan Seigerman

Work Performance Price Targets & Ratings Chart

Analyst Evan Seigerman, currently employed at BMO, carries an average stock price target met ratio of 62.78% that have a potential upside of 20.5% achieved within 147 days.

Evan Seigerman’s has documented 412 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BMY, Bristol-Myers Squibb Company at 01-Nov-2024.

Wall Street Analyst Evan Seigerman

Analyst best performing recommendations are on STSA (SATSUMA PHARMACEUTICALS).
The best stock recommendation documented was for STSA (SATSUMA PHARMACEUTICALS) at 3/2/2021. The price target of $6.5 was fulfilled within 1 day with a profit of $0.25 (4%) receiving and performance score of 40.

Average potential price target upside

ACRX AcelRx Pharmaceuticals AIMT Aimmune Therapeutics AMGN Amgen BIIB Biogen BMY Bristol-Myers Squibb Company GILD Gilead Sciences GRTX Galera Therapeutics INCY yte LLY Eli Lilly and Company MRTX Mirati Ther NBIX Neurocrine Biosciences PFE Pfizer REGN Regeneron Pharmaceuticals STSA Satsuma Pharmaceuticals VRTX Vertex Pharmaceuticals NUVB Nuvation Bio REPL Replimune Group CADL Candel Therapeutics MGNX MacroGenics MRK Merck mpany GLPG Galapagos NV ADR IKNA Ikena Oncology MORF Morphic

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

1 years 1 months 11 days ago
(25-Sep-2023)

0/3 (0%)

$95.4 (213.90%)

Buy

$160

2 years 11 months 4 days ago
(01-Dec-2021)

0/1 (0%)

$74.6 (87.35%)

Sell

$16.6

$15.47 (1369.03%)

$16.8

3 years 11 months 30 days ago
(06-Nov-2020)

4/4 (100%)

$-12.4 (-42.76%)

335

Buy

$120

$118.58 (8350.70%)

5 years 5 months 27 days ago
(09-May-2019)

0/1 (0%)

$56.4 (88.68%)

Buy

$200

$198.87 (17599.12%)

$140

6 years 3 days ago
(02-Nov-2018)

0/2 (0%)

$104 (108.33%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Evan Seigerman is most bullish on?

Potential upside of $346.4 has been obtained for REGN (REGENERON PHARMACEUTICALS)

Which stock is Evan Seigerman is most reserved on?

Potential downside of -$24.13 has been obtained for INCY (YTE)

What Year was the first public recommendation made by Evan Seigerman?

On 2019

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?